The European Patent Office (EPO) has published patent application EP4518972A2, filed by RegenxBio Inc., concerning vectorized anti-complement antibodies and complement agents for therapeutic administration. The patent application, designated for various European states, details specific antibody constructs and their use in treating conditions related to complement system activity.

This publication represents the grant of a patent, not a regulatory rule or guidance with immediate compliance obligations for regulated entities. Companies in the pharmaceutical and biotechnology sectors, particularly those involved in antibody development or complement pathway research, should note this patent for intellectual property and competitive landscape awareness. No specific actions or deadlines are imposed by this patent publication.